BioPharma Terug naar discussie overzicht

PRW - Pro-Pharmaceuticals Inc.

1. NADO 9 april 2007 18:51

   auteur info

   • NADO

     Lid sinds: 07 nov 2001

     Laatste bezoek: 10 mei 2023

   • Aanbevelingen

     Ontvangen: 182

     Gegeven: 11

   •    Aantal posts: 1.240

   + 10 %
   HEB IK IETS GEMIST ??
2. welshterrier 5 9 april 2007 20:43

   auteur info

   • welshterrier 5

     Lid sinds: 23 mrt 2004

     Laatste bezoek: 25 mrt 2025

   • Aanbevelingen

     Ontvangen: 291

     Gegeven: 1101

   •    Aantal posts: 20.113

   kan niks vinden, net 0,79 mooi
3. [verwijderd] 9 april 2007 20:48

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   nu $ 0.81! Gaat hard!
4. welshterrier 5 9 april 2007 20:50

   auteur info

   • welshterrier 5

     Lid sinds: 23 mrt 2004

     Laatste bezoek: 25 mrt 2025

   • Aanbevelingen

     Ontvangen: 291

     Gegeven: 1101

   •    Aantal posts: 20.113

   vreemd zonder nieuws???
   nu al 85 gezien!!!
5. welshterrier 5 9 april 2007 21:17

   auteur info

   • welshterrier 5

     Lid sinds: 23 mrt 2004

     Laatste bezoek: 25 mrt 2025

   • Aanbevelingen

     Ontvangen: 291

     Gegeven: 1101

   •    Aantal posts: 20.113

   net op 86 verkocht, mooi in de pocket
6. NADO 9 april 2007 21:24

   auteur info

   • NADO

     Lid sinds: 07 nov 2001

     Laatste bezoek: 10 mei 2023

   • Aanbevelingen

     Ontvangen: 182

     Gegeven: 11

   •    Aantal posts: 1.240

   Van winst nemen is nog nooit iemand slechter geworden.
   Ijzer smeden als het heet is
   
7. Picardo 10 april 2007 16:12

   auteur info

   • Picardo

     Lid sinds: 07 sep 2006

     Laatste bezoek: 26 jul 2024

   • Aanbevelingen

     Ontvangen: 15

     Gegeven: 8

   •    Aantal posts: 103

   Alweer +15% ..
   
   Weet iemand een reden voor deze mooie stijging in 2 dagen ?
8. welshterrier 5 10 april 2007 17:41

   auteur info

   • welshterrier 5

     Lid sinds: 23 mrt 2004

     Laatste bezoek: 25 mrt 2025

   • Aanbevelingen

     Ontvangen: 291

     Gegeven: 1101

   •    Aantal posts: 20.113

   geen idee,maar ben vanmiddag weer ingestapt, gister te vroeg er uit.
   maar ben waakzaam 15 febr jl ging dit aandeel ook na een grote stijging ineens in een paar uur tijd flink naar beneden.
9. Nel 10 april 2007 21:36

   auteur info

   • Nel

     Lid sinds: 04 apr 2004

     Laatste bezoek: 18 mrt 2025

   • Aanbevelingen

     Ontvangen: 1417

     Gegeven: 219

   •    Aantal posts: 27.771

   The Company recently announced that it is scheduled to meet with the U.S. Food & Drug Administration (FDA) on April 11th to discuss data and plans for submitting a New Drug Application (NDA), under Section 505 (b)(2) for DAVANAT® to be co-administered with 5-Fluorouracil (5-FU) to treat cancer patients. The Company is using DAVANAT® to obtain more timely and efficient marketing approval of new formulations of previously approved therapeutics which incorporate the Company's proprietary drug target delivery compound through Section 505 (b)(2). The FDA has approved galactomannans for other uses and deliveries, such as oral or topical delivery for food, pills and cosmetics. The Company is seeking approval for co-administration of DAVANAT® (a galactomannan) with 5-FU for intravenous injection for the treatment of cancer.
   
   
10. [verwijderd] 10 april 2007 22:21

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    voor de Russen onder ons:
    
    Компания недавн объявила что оно запланировано встретить еду США & администрацию снадобья (FDA) на ййтю -го апреля для того чтобы обсудить данные и планы для представлять новое применение снадобья (NDA), под разделом 505 (b)(2) для DAVANAT®, котор нужноco-administered с 5-Fluorouracil (5-FU) для того чтобы обработать пациентов рака. Компания использует DAVANAT® для того чтобы получить более своевременное и более эффективное утверждение маркетинга новых образований ранее approved терапевтики включают смесь поставки цели снадобья компании собственническую до раздел 505 (b)(2). FDA одобрил galactomannans для других польз и поставок, such as устно или злободневная поставка для еды, пилюлек и косметик. Компания изыскивает утверждение для чо-administraqii DAVANAT® (galactomannan) с 5-FU для внутривенной впрыски для обработки рака.
    
    
    
11. jip banaan! 10 april 2007 22:22

    auteur info

    • jip banaan!

      Lid sinds: 10 feb 2005

      Laatste bezoek: 22 feb 2024

    • Aanbevelingen

      Ontvangen: 2697

      Gegeven: 9726

    •    Aantal posts: 13.304

    quote:

    domus muris schreef:

    voor de Russen onder ons:
    
    Компания недавн объявила что оно запланировано встретить еду США & администрацию снадобья (FDA) на ййтю -го апреля для того чтобы обсудить данные и планы для представлять новое применение снадобья (NDA), под разделом 505 (b)(2) для DAVANAT®, котор нужноco-administered с 5-Fluorouracil (5-FU) для того чтобы обработать пациентов рака. Компания использует DAVANAT® для того чтобы получить более своевременное и более эффективное утверждение маркетинга новых образований ранее approved терапевтики включают смесь поставки цели снадобья компании собственническую до раздел 505 (b)(2). FDA одобрил galactomannans для других польз и поставок, such as устно или злободневная поставка для еды, пилюлек и косметик. Компания изыскивает утверждение для чо-administraqii DAVANAT® (galactomannan) с 5-FU для внутривенной впрыски для обработки рака.
    
    
    
    

    hahahahahahahahabahanaan!!
12. [verwijderd] 10 april 2007 22:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ja, neef, ook voor de nederlanders die het engels niet zo machtig zijn.....
    
    Het Bedrijf kondigde onlangs dat het gepland het Beleid van het Voedsel & van de Drug van de V.S. (FDA) op 11 is samenkomen April om gegevens en plannen te bespreken voor het indienen van een Nieuwe Aanvraag van de Drug (NDA), in het kader van Sectie 505 (b) (2) voor DAVANAT® dat met 5-fluorouracil (5-FU) aan mede- moet wordenbeheerd om kankerpatiënten te behandelen. Het Bedrijf gebruikt DAVANAT® om geschiktere en efficiënte marketing goedkeuring van nieuwe formuleringen van eerder goedgekeurde therapeutiek te verkrijgen die de van het de drugdoel van het Bedrijf merkgebonden de leveringssamenstelling door Sectie 505 opnemen (b) (2). FDA heeft galactomannans voor andere gebruik en leveringen, zoals mondelinge of actuele levering voor voedsel, pillen en schoonheidsmiddelen goedgekeurd. Het Bedrijf streeft naar goedkeuring van mede-beleid van DAVANAT® (galactomannan) met 5-FU voor intraveneuze injectie voor de behandeling van kanker.
    
    
    
13. [verwijderd] 11 april 2007 14:18

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pro-Pharmaceuticals says FDA seeks more information on Davanat
    
    April 11 (Reuters) - Pro-Pharmaceuticals Inc. (PRW.A: Quote, Profile , Research) said U.S. regulators have asked for the chemistry, manufacturing and controls information to support a new drug application for its lead drug candidate Davanat to be co-administered with chemotherapy drug 5-Fluorouracil to treat cancer patients. (Reporting by Rakesh Sharma in Bangalore)
    
    tinyurl.com/25sejg
    
14. welshterrier 5 11 april 2007 16:12

    auteur info

    • welshterrier 5

      Lid sinds: 23 mrt 2004

      Laatste bezoek: 25 mrt 2025

    • Aanbevelingen

      Ontvangen: 291

      Gegeven: 1101

    •    Aantal posts: 20.113

    snap niks meer van dit aandeel, net nog hoog 96 nu weer 80, en 77 gezien omzet ruim 300k
15. [verwijderd] 11 april 2007 16:51

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Junk stuff.....return to 30 cents !!!!!
16. prrrrr 11 april 2007 17:02

    auteur info

    • prrrrr

      Lid sinds: 06 mrt 2005

      Laatste bezoek: 12 sep 2024

    • Aanbevelingen

      Ontvangen: 41

      Gegeven: 8

    •    Aantal posts: 2.350

    RT AUB
17. [verwijderd] 11 april 2007 17:09

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    79 cents.
18. [verwijderd] 11 april 2007 20:33

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Vanavond kijken we niet zo nauw, en houden ook de Chinese forumlezers goed op de hoogte;
    
    讚成配藥認為糧食與藥物管理局尋求更多資訊關於Davanat (路透社) 4月11 日- 讚成Pro-Pharmaceuticals Inc. (PRW.A: 行情, 外形, 研究) 認為美國管理者請求化學、製造業和控制資訊支持對它的主角藥物候選人的新藥物申請Davanat co 被執行與化療藥物5-Fluorouracil 治療癌症患者。(報告由Rakesh Sharma 在班格洛)
    
    voor degenen die wat moeite hebben met de bovenstaande tekst zal ik de vertaling geven;
    
    De pro-geneesmiddelen zegt FDA meer informatie over Davanat verkrijgt 11 April (Reuters) - Pro-Pharmaceuticals Inc. (PRW. A: het Citaat, het Profiel, regelgevers van de V.S. van het Onderzoek) de bovengenoemde hebben om de chemie, productie en controles informatie gevraagd om een nieuwe drugtoepassing voor zijn kandidaat Davanat te steunen van de looddrug dat met chemotherapiedrug 5-fluorouracil mede- moet wordenbeheerd om kankerpatiënten te behandelen. (Rapporterend door Rakesh Sharma in Bangalore) tinyurl.com/25sejg
    
    
    
19. Picardo 12 april 2007 15:47

    auteur info

    • Picardo

      Lid sinds: 07 sep 2006

      Laatste bezoek: 26 jul 2024

    • Aanbevelingen

      Ontvangen: 15

      Gegeven: 8

    •    Aantal posts: 103

    Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
    Thursday April 12, 7:00 am ET
    
    NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a developer of novel first-in-class carbohydrate compounds, received comments from the U.S. Food & Drug Administration (FDA) relative to its plans for submitting a New Drug Application (NDA), under Section 505 (b)(2) for DAVANAT®, as a functional excipient, to be co-administered with 5-Fluorouracil (5-FU) to treat cancer patients.
    ADVERTISEMENT
    
    
    "In March, we sent the FDA substantial information on chemistry and completed pre-clinical and clinical data, along with a list of questions to submit an NDA to allow DAVANAT®, to be used as a functional excipient, intravenously with 5-FU, for cancer applications for a filing under Section 505 (b)(2)," said David Platt, Ph.D., President & Chief Executive Officer, Pro-Pharmaceuticals, Inc. "The letter response from the FDA was in line with our expectation. The FDA's response provides us with a clear roadmap in terms of what additional information, primarily manufacturing, they need to allow our NDA submission. No additional toxicology or clinical tests or trials are required. We plan to file an NDA submission as soon as we complete the additional manufacturing information needed."
    
    DAVANAT® as a Functional Excipient
    
    Excipients are the materials other than the active pharmaceutical ingredients incorporated into dosage forms to play specific functional roles, including modulating solubility, increasing stability and bioavailability, and play critical roles in the effectiveness, safety, potency, purity and stability of a product. In complex products such as chemotherapeutics, the functional role of an excipient is also important when used as a drug delivery system to reduce toxicity and/or increase efficacy.
    
    The Company is using Section 505 (b)(2) to obtain more timely and efficient marketing approval of new formulations of previously approved therapeutics which incorporate the Company's proprietary drug target delivery compound. The Company is seeking approval for co-administration of DAVANAT® (a galactomannan) with FDA-approved 5-FU for intravenous injection for the treatment of cancer. 5-FU is one of the most widely used chemotherapy drugs in the world and is used to treat various types of cancers, including colorectal, breast and gastrointestinal.
    
    About Section 505 (b)(2)
    
    Section 505 (b)(2) allows the FDA to approve a drug on the basis of data in the scientific literature or data previously cited by the FDA as the basis for the approval of related drugs. This procedure makes it potentially faster for drug developers to obtain approval of new formulations of drugs based, in part, on proprietary data of the developer of the original drug. Section 505 (b)(2) of the U.S. Food, Drug & Cosmetic Act permits the FDA to approve a NDA in part on the basis of published literature or on a previous finding of safety or effectiveness of a drug. A 505 (b)(2) application can apply to new chemical entities or to changes to previously approved drugs. Galactomannan are approved for formulation and deliveries, such as oral, topical and vaginal delivery of drugs. DAVANAT® extends the use of galactomannan to the delivery of chemotherapeutic drugs. In this application, DAVANAT® is co-administered with 5-FU for intravenous delivery.
    
    The Company is also continuing its clinical development plan for DAVANAT® in combination with 5-FU and other chemotherapy and biological drugs, such as leucovorin and AVASTIN®. The Company plans to initiate a Phase lll trial after reporting interim results from the ongoing Phase ll trials. The FDA provided comments on the design of the Company's Phase lll trial for colorectal cancer.
    
    About DAVANAT®
    
    DAVANAT®, the Company's lead product candidate, is a polysaccharide, carbohydrate polymer, composed of mannose and galactose (galactomannan). The Company believes DAVANAT®'s mechanism of action is based upon binding to lectins on the surface of cancer cells. Lectins are carbohydrate-binding proteins found on cell surfaces. It is theorized that DAVANAT® targets specific lectin receptors (Galectins) that are over-expressed on cancer cells. Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis. This form of targeted delivery may allow for higher doses of chemotherapy administration with no increase in toxicity.
    
    Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience®
    
    Pro-Pharmaceuticals is a development stage pharmaceutical company engaged in the discovery, development and commercialization of first-in-class carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases. The Company's initial focus is the development and commercialization of a new generation of anti-cancer treatments using carbohydrate polymers with the intent of enhancing the safety and efficacy of standard cancer agents. The Company's technology capitalizes on the natural property of carbohydrates to increase the efficacy and reduce the toxicity of chemotherapeutics; "rescue" drugs that were shelved for toxicity or "half-life" issues; increase the solubility of existing drugs, and develop carbohydrate polymers as new chemical entities.
    
    The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT®, in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin®). Results show that DAVANAT® exhibits a broad spectrum of activity with tested drugs. The Company is developing additional carbohydrate-based therapeutic compounds that are currently in the pre-clinical stage of development. Founded in 2000, the Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.
    
    FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with pre-clinical and clinical trials of our product candidates; our limited experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales, distribution and marketing of our potential products; possible development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of our proprietary technology; compliance with and
20. Picardo 12 april 2007 15:49

    auteur info

    • Picardo

      Lid sinds: 07 sep 2006

      Laatste bezoek: 26 jul 2024

    • Aanbevelingen

      Ontvangen: 15

      Gegeven: 8

    •    Aantal posts: 103

    and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with pre-clinical and clinical trials of our product candidates; our limited experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales, distribution and marketing of our potential products; possible development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of our proprietary technology; compliance with and change of government regulation of our activities, facilities and personnel; uncertainties as to the extent of reimbursement for our potential products by government and private health insurers; our dependence on key personnel; our history of operating losses and accumulated deficit; and economic conditions related to the biotechnology and bio-pharmaceutical industry. We cannot assure you that we have identified all the factors that create uncertainties. Readers should not place undue reliance on forward-looking statements.
    
    More information about those risks and uncertainties is contained and discussed in the "Management Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections of the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.
    
    DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals. AVASTIN is a registered trademark of Genentech, Inc.